TNG — Transgene SA Income Statement
0.000.00%
Last trade - 00:00- €115.57m
- €99.09m
- €6.08m
Annual income statement for Transgene SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.34 | 17 | 10 | 7.63 | 6.08 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 33.3 | 40.5 | 39.9 | 37.7 | 41.7 |
| Operating Profit | -24 | -23.5 | -29.9 | -30 | -35.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17.2 | -19.5 | -32.8 | -22.3 | -34 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.2 | -19.5 | -32.8 | -22.3 | -34 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.2 | -19.5 | -32.8 | -22.3 | -34 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.2 | -19.5 | -32.8 | -22.3 | -34 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.206 | -0.214 | -0.33 | -0.222 | -0.291 |
| Dividends per Share |